View Author
patient therapy resistance treatment hepatitis combination level combination therapy month hepatitis b hepatology hbv dna levels study response tdf treatment tenofovir ef ficacy tdf monotherapy hbv dna range lamivudine genotypic virus liver monotherapy germany genotypic resistance adefovir baseline analysis hbeag hepatitis b virus hepatology 2012 vol serum entecavir mutation disease liver disease tenofovir disoproxil fumarate rescue therapy adv resistance ficacy genotypic adv resistance signi cohort probability department failure table bommel lactic acidosis observation period hbsag safety infection adefovir dipivoxil variant virologic response lam resistance duration alt levels observation development period cirrhosis adherence treatment failure rescue nucleoside virologic university hospital eppendorf suppression hbv-dna hbv dna level 400 copies /ml multidrug journal 0.5 mg /dl analogue liver cirrhosis
2 Most Recent Publications
|
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study
(Article)
Petersen, J. Ratziu, V. Berg, T. Sarrazin, C. Lutgehetmann, M. Buggisch, P. Buti, M. Janssen, H.L.A. Brown, A. Lampertico, P. Schollmeyer, J. Zoulim, F. Wedemeyer, H. Sterneck, M. |
2012-03-01
|
|
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues
(Article)
Bömmel, F. van Man, R.A. de Sarrazin, C. Böcher, W.O. Spengler, U. Wasmuth, H.E. Reinders, J.G.P. Möller, B. Rhode, P. Feucht, H.H. Wiedenmann, B. Berg, T. Wedemeyer, H. Deterding, K. Petersen, J. Buggisch, P. Erhardt, A. Hüppe, D. Stein, K. Trojan, J. |
2010-01-01
|
